Strong Response Rate for Claseprubart in CIDP Supports Continuing to Controlled Phase of Trial Dianthus Therapeutics announced promising early results for claseprubart, a next-generation C1s inhibitor designed to treat CIDP.

Dianthus Therapeutics announced an early “go” decision for #Claseprubart for the treatment of chronic inflammatory demyelinating polyneuropathy (#CIDP).

Read here: https://bit.ly/4dfTZeI

#RareDisease #ClinicalTrial #CAPTIVATE